Literature DB >> 7601206

Melatonin receptors mediate potentiation of contractile responses to adrenergic nerve stimulation in rat caudal artery.

D N Krause1, V E Barrios, S P Duckles.   

Abstract

The hormone melatonin potentiated contractile responses to adrenergic nerve stimulation in isolated ring segments of rat caudal artery. This effect was inhibited by the melatonin receptor antagonist luzindole but not by the serotonin 5-HT2 receptor antagonist ketanserin. Melatonin had no direct effects on vascular tone. Melatonin agonists potentiated contractile responses with a relative order of potency (2-iodomelatonin, EC50 = 0.6 nM; melatonin, EC50 = 4.7 nM; N-acetylserotonin, EC50 = 1.5 microM) that is consistent with the melatonin ML1 receptor subtype. Melatonin also potentiated contractions elicited by exogenous norepinephrine and produced its effects in the absence of an intact endothelium. These data suggest that melatonin acts on receptors in the smooth muscle. The caudal artery provides a useful functional assay for pharmacological analysis of melatonin receptors. Physiologically, melatonin may activate its receptors at night to influence thermoregulation in the rat by enhancing the effects of sympathetic input to the caudal artery.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7601206     DOI: 10.1016/0014-2999(95)00028-j

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  13 in total

Review 1.  Melatonin membrane receptors in peripheral tissues: distribution and functions.

Authors:  Radomir M Slominski; Russel J Reiter; Natalia Schlabritz-Loutsevitch; Rennolds S Ostrom; Andrzej T Slominski
Journal:  Mol Cell Endocrinol       Date:  2012-01-08       Impact factor: 4.102

Review 2.  Functional MT1 and MT2 melatonin receptors in mammals.

Authors:  Margarita L Dubocovich; Magdalena Markowska
Journal:  Endocrine       Date:  2005-07       Impact factor: 3.633

3.  Molecular and pharmacological evidence for MT1 melatonin receptor subtype in the tail artery of juvenile Wistar rats.

Authors:  K N Ting; N A Blaylock; D Sugden; P Delagrange; E Scalbert; V G Wilson
Journal:  Br J Pharmacol       Date:  1999-06       Impact factor: 8.739

4.  Cardiovascular effects of melatonin in hypertensive patients well controlled by nifedipine: a 24-hour study.

Authors:  P Lusardi; E Piazza; R Fogari
Journal:  Br J Clin Pharmacol       Date:  2000-05       Impact factor: 4.335

5.  Management of sleep disorders in stroke.

Authors:  Kyoung Bin Im; Scott Strader; Mark Eric Dyken
Journal:  Curr Treat Options Neurol       Date:  2010-09       Impact factor: 3.598

6.  International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors.

Authors:  Margarita L Dubocovich; Philippe Delagrange; Diana N Krause; David Sugden; Daniel P Cardinali; James Olcese
Journal:  Pharmacol Rev       Date:  2010-07-06       Impact factor: 25.468

7.  Treatment of sleep disorders in elderly patients.

Authors:  John J Harrington; Alon Y Avidan
Journal:  Curr Treat Options Neurol       Date:  2005-09       Impact factor: 3.598

Review 8.  Melatonin and the skeleton.

Authors:  A K Amstrup; T Sikjaer; L Mosekilde; L Rejnmark
Journal:  Osteoporos Int       Date:  2013-05-29       Impact factor: 4.507

Review 9.  Melatonin receptors, heterodimerization, signal transduction and binding sites: what's new?

Authors:  R Jockers; P Maurice; J A Boutin; P Delagrange
Journal:  Br J Pharmacol       Date:  2008-05-19       Impact factor: 8.739

10.  Melatonin inhibits nitric oxide signaling by increasing PDE5 phosphorylation in coronary arteries.

Authors:  Praveen Shukla; Chengwen Sun; Stephen T O'Rourke
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-10-19       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.